Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2025 | $34.00 | Market Perform → Outperform | BMO Capital Markets |
| 4/30/2024 | $19.00 | Buy | Guggenheim |
| 6/17/2022 | $7.00 | Outperform | BMO Capital Markets |
| 6/9/2022 | Outperform → Mkt Perform | William Blair | |
| 9/10/2021 | $23.00 → $26.00 | Buy | Stifel |
8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)
10-Q - PRECISION BIOSCIENCES INC (0001357874) (Filer)
8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)
BMO Capital Markets upgraded Precision BioSciences from Market Perform to Outperform and set a new price target of $34.00
Guggenheim initiated coverage of Precision BioSciences with a rating of Buy and set a new price target of $19.00
BMO Capital Markets initiated coverage of Precision BioSciences with a rating of Outperform and set a new price target of $7.00
- Strengthens the Company's intellectual property portfolio for lead in vivo program PBGENE-HBV with U.S. patent protection into 2042- - Phase 1 ELIMINATE-B trial progressing through clinical investigation with dosing of Cohort 3 initiated in Third Quarter of 2025- Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will be issued U.S. Patent No. 12,410,418 by the U.S. Patent and Trademark Office on September 9, 2025, titled "Optimized engineered meganucleases having specificity for a recognition sequence in the
iECURE, Inc., a genome editing company focused on the development of variant-agnostic in vivo targeted gene insertion therapies for the treatment of liver disorders with significant unmet need, today announced that additional data from the ongoing OTC-HOPE clinical trial evaluating its candidate ECUR-506 in neonatal onset ornithine transcarbamylase (OTC) deficiency will be presented at the 6th International Symposium on Urea Cycle Disorders (UCDs), taking place September 1-2, 2025 in Kyoto, Japan, and the 15th International Congress of Inborn Errors of Metabolism (ICIEM), taking place September 3-6, 2025 in Kyoto, Japan. The poster presentations will build upon data the company originally
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the second quarter 2025 and provide a business update on August 7, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics ma
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- Wholly owned programs PBGENE-HBV for Chronic Hepatitis B virus and PBGENE-PMM for m.3243 mitochondrial disease on track for IND and/or CTA submissions in 2024 and 2025, respectively - Expanded Hepatitis Scientific Advisory Board with addition of world-class clinical investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. - Sufficient capital to realize Phase 1 clinical data for multiple in vivo gene editing programs; Expected cash runway into the second half of 2026 - Regained control of three advanced preclinical programs for development internally or with partners, including a novel gene editing approach for Duchenne Muscular Dystrophy Precision BioSciences, Inc. (NASDA
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced the appointment of Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. to its Hepatitis Scientific Advisory Board (SAB). Dr. Sulkowski and Dr. Feld will join Raymond Schinazi, Ph.D., DSc, inaugural member of Precision's Hepatitis SAB, to provide counsel and deepen the Company's scientific and clinical expertise ahead of Precision's anticipated Investigational New Drug (IND) and/or Clinical Trial Application (CTA) submission of PBGE
New Director Brings Proven Financial and Leadership Experience Fifth Director Added to the Board of Directors Since April 2021 Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Melinda Brown has been appointed as a Director on the Company's Board of Directors and Chair of the Board's Audit Committee. Ms. Brown is a financial expert with proven experience leading accounting, finance and enterprise risk management teams in large, public companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the second quarter 2025 and provide a business update on August 7, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics ma
- PBGENE-DMD is a first-in-class in vivo gene editing approach for the majority of Duchenne Muscular Dystrophy patients impacted by dystrophin mutations in the most common ‘hot spot' region between exons 45-55 - - Final clinical candidate PBGENE-DMD demonstrates compelling preclinical data for durably improving functional benefit over time - - Precision targeting to submit an Investigational New Drug (IND) and/or Clinical Trial Application (CTA) for PBGENE-DMD in 2025 with clinical data expected in 2026 - - Precision to host a webcast and conference call on Thursday, May 15, 2025 at 8:00 AM ET - Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing i
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the first quarter 2025 and provide a business update on May 15, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may ena
SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)
SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)
SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)